Menu Back toSpeakers

DIA/FDA Biostatistics Industry and Regulator Forum

This event is now offered in a new entirely virtual format.


  • Mouna  Akacha, PhD

    Mouna Akacha, PhD

    • Group Head of Statistical Methodology
    • Novartis Pharma AG, Switzerland

    Mouna Akacha is the Group Head of the Statistical Methodology group of Novartis Pharma AG, based in Basel, Switzerland. She and her team provide internal advice for clinical projects in all development phases and therapeutic areas. She is engaged in developing and implementing innovative statistical methods for clinical projects covering estimand discussions and approaches for missing data, longitudinal data, and recurrent event data. Before joining Novartis, Akacha studied mathematics at the University of Oldenburg in Germany. She holds a PhD in statistics from the University of Warwick in the United Kingdom.

  • Brenda  Crowe, PhD

    Brenda Crowe, PhD

    • Senior Research Advisor, Global Statistical Sciences
    • Eli Lilly and Company, United States

    Brenda Crowe is a Senior Research Advisor at Eli Lilly and Company. She has more than 20 years of pharmaceutical industry experience. She obtained a PhD in Statistics from the University of Toronto. She has worked extensively with both clinical trials and observational studies. She has participated in or led several expert teams. As examples, she was a co-chair of the cross-industry Safety Planning, Evaluation and Reporting team, and served as the lead editor of the Council for International Organizations of Medical Sciences report on meta-analysis of safety data. She is a fellow of the American Statistical Association.

  • Jonathan  Haddad, MPH

    Jonathan Haddad, MPH

    • HIV Disease Area Head, Clinical Statistics
    • GlaxoSmithKline, United States

    More than 20 years' experience in Biotech, CRO & Pharma. Built and managed biostatistics, statistical programming & data management groups. Clinical trial experience in Oncology, Inflammatory Diseases, Dermatology & HIV. Keen interest in functional alignment, statistics in decision-making & quantitative Benefit-Risk methodology.

  • Rima  Izem, PhD

    Rima Izem, PhD

    • Biostatistician, Division of Biostatistics and Study Methodology
    • Children’s Research Institute at Children’s National Medical Center , United States

    Rima Izem is an Associate Professor of Pediatrics at Children’s National Research Institute and the George Washington University, since December 2018. At Children’s National, she supports different aspects of clinical research as they relate to study design and statistical analyses of clinical and epidemiological studies in the pediatric population. Her research interests include study design in rare diseases, causal inference, and signal detection in large electronic healthcare databases. Her focus is to optimize incorporating information on growth and development into study design and quantitative methods in studies in children. Prior to joining Children’s National, she was a senior statistician at the Food and Drug Administration (FDA).

  • Shiowjen  Lee, PhD

    Shiowjen Lee, PhD

    • Deputy Director, Division of Biostatistics, OBE, CBER
    • FDA, United States

  • Cristiana  Mayer, DrSc, PhD

    Cristiana Mayer, DrSc, PhD

    • Director, Statistics and Decision Sciences
    • Janssen Research & Development, LLC, United States

    Cristiana Mayer is Director at Statistics and Decision Sciences, at Janssen R&D, Johnson & Johnson, with 20+ years of experience in the pharmaceutical industry. Cristiana is also the Head of the Adaptive Clinical Trials Center of Excellence at Janssen, and Vice-Chair of the DIA Adaptive Design Working Group. After 15 years in Biostatistics where she held roles of increasing responsibility in different therapeutic areas including hematology, neuroscience, immunology, and metabolism, she worked 5 years in Statistical Modeling & Methodology group at Janssen. In 2018 Cristiana has taken a functional management role in the IDV Biostatistics group. Her current interests are in CID and platform trials and Bayesian designs.

  • Lei  Nie, PhD

    Lei Nie, PhD

    • Associate Director of Biometrics II, Office of Biostatistics, OTS, CDER
    • FDA, United States

    Lei Nie has worked for FDA since 2007 and previously worked for Georgetown University where he served as the director of Graduate Study in the Department of Biostatistics, Bioinformatics, and Biomathematics. He graduated from the University of Illinois at Chicago with a Ph.D. in statistics in 2002. He is an elected ASA Fellow and has authored/authored a total of 99 peer reviewed publications.

  • Frank W. Rockhold, PhD, MSc

    Frank W. Rockhold, PhD, MSc

    • Professor of Biostatistics
    • Duke Clinical Research Institute, Duke University Medical Center, United States

    Frank is a full-time Professor of Biostatistics and Bioinformatics at Duke University Medical Center and Managing Partner of HunterRockhold, Inc., which provides strategic consulting to Industry and Government. His career includes senior positions at Lilly, Merck, and GlaxoSmithKline, where he retired as Chief Safety Officer. He has held faculty appointments at six different universities, served as Chairman of CDISC, and is past president of the Society for Clinical Trials. Frank holds a BA in Statistics and an ScM and PhD in Biostatistics. Frank is a Fellow of the American Statistical Association, The Royal Statistical Society, and the Society for Clinical Trials and is widely published across a wide variety of research topics.

  • William  Wang, PhD

    William Wang, PhD

    • Executive Director, Clinical Safety Statistics, BARDS
    • Merck Research Laboratories, United States

    Dr. William (Bill) Wang is an executive director, clinical safety statistics, Merck Research Laboratories. He has over 25 years of experience in the pharmaceutical industry, with ~18 years with Merck & Co Inc. He is co-chairing the ASA safety working group, and a deputy topics-leader in the ICH E17 working group on multi-regional clinical trials. Dr Bill Wang was elected as a Fellow of American Statistical Association (2018) and received the DIA Global Inspire Award in 2017 .

  • Aloka  Chakravarty, PhD

    Aloka Chakravarty, PhD

    • Deputy Director, Office of Biostatistics, Office of Translational Sciences, CDER
    • FDA, United States

    Dr. Chakravarty joined CDER in 1992. She is an internationally recognized thought leader in the area of safety evaluation, surrogate markers and biomarkers in drug development and has presented and published widely on it. Dr. Chakravarty received the FDA Award of Merit in 2008 and Dr. Frances O. Kelsey Drug Safety Excellence Award in 2012.She served as an Adjunct Faculty in Depart. of Statistics, Foundation for Advanced Education in the Sciences, NIH. She received her PhD in Statistics from Temple University, and M.Stat from Indian Statistical Institute. Dr. Chakravarty is a Fellow of ASA and an Associate Editor of Statistics in Biomedical Research.

  • Karen Lynn Price, PhD

    Karen Lynn Price, PhD

    • Research Fellow, Statistical Innovation Center/Design Hub
    • Eli Lilly and Company, United States

    Karen received her Ph.D. in Statistics from Baylor University in 2001, and joined Eli Lilly and Company at that time. She is currently Research Fellow at Eli Lilly and Company where she leads the Statistical Innovation Center, a team that focuses on innovative design and analysis of clinical trials. In 2011, Karen helped form and led the DIA Bayesian Scientific Working Group and currently serves as past-chair. This group includes members in Industry, Regulatory, and Academia. Her research interests include Bayesian design and analysis of clinical trials and master protocols. In 2016, Karen was elected a Fellow of the American Statistical Association.

  • Mat  Soukup, PhD

    Mat Soukup, PhD

    • Deputy Director, Division of Biometrics VII, OB, OTS CDER
    • FDA, United States

    Following his educational endeavors in statistics at the University of Minnesota-Morris and the University of Virginia, Mat joined FDA/CDER in September 2004. His first 6 years were spent reviewing dermatology and dental products before joining the Division of Biometrics 7 as Team Lead and later as Deputy Division Director. In these roles, Mat is involved in the quantitative assessment of safety covering a spectrum of statistical issues ranging from retrospective assessment of safety signals to prospective design of safety outcome trials.

  • Jeffrey S Barrett, PhD

    Jeffrey S Barrett, PhD

    • Head Quantitative Sciences
    • Bill & Melinda Gates Medical Research Institute , United States

  • Scott  Komo, DrPH

    Scott Komo, DrPH

    • Lead Mathematical Statistician, Office of Translational Sciences, CDER
    • FDA, United States

    Scott Komo is a Senior Statistical Reviewer in the Office of Biostatistics, Center for Drug Evaluation and Research, FDA. He is involved with the design, analysis, and interpretation of studies that use clinical outcome assessments. He has supported multiple medical areas since joining the FDA in 1999. He received a BA in Chemistry from the University of California, Davis and an MS and DrPH in Biostatistics from the University of California, Los Angeles.

  • Pallavi  Mishra-Kalyani, PhD, MS

    Pallavi Mishra-Kalyani, PhD, MS

    • Lead Mathematical Statistician
    • FDA, United States

    Pallavi Mishra-Kalyani, Ph.D. is a Team Leader in the Division of Biometrics V, Office of Biostatistics which supports Office of Oncology Drugs at the Center for Drug Evaluation and Research (CDER). Since joining the Food and Drug Administration (FDA) in 2015, Dr. Mishra-Kalyani has contributed to the efforts to address the statistical issues related to the potential use of Real World Data and Real World Evidence for regulatory purposes. Her research interests include statistical methods for observational data, causal inference, and non-randomized trial design. Dr. Mishra-Kalyani received her Ph.D. in Biostatistics from Emory University and her Master’s degree in Epidemiology from the T.H. Chan School of Public Health at Harvard University.

  • Dionne  Price, PhD

    Dionne Price, PhD

    • Director, Division of Biometrics IV, Office of Biostatistics, OTS, CDER
    • FDA, United States

    Dr. Price is the Director of the Division of Biometrics IV providing leadership of analytical assessments in a regulatory setting. On the Senior Leadership Team and Statistical Policy Council, Dr. Price promotes collaborative efforts to advance the use of complex innovative trial designs. An invited speaker at conferences world-wide, she has served as Chair of ASA’s Biopharmaceutical Section and on the Regional Committee of the Eastern North American Region of IBS. She is a Fellow of the ASA and an elected VP. With an MS in Biostatistics from UNC, and PhD from Emory, her research interests focus on clinical trial designs. She has co-authored papers in Statistics in Medicine, Clinical Trials, and Statistics in Biopharmaceutical Research.

  • Gregory  Levin, PhD

    Gregory Levin, PhD

    • Deputy Director, DBIII, OB, OTS, CDER
    • FDA, United States

    Greg Levin is a supervisory mathematical statistician at the Center for Drug Evaluation and Research within FDA. He joined FDA after receiving a PhD in biostatistics from the University of Washington in 2012. At FDA, Greg has helped regulate products across a wide range of therapeutic areas. His research interests include missing data, adaptive design, labeling, and making real-world inferences from clinical trials.

  • Sylva  Collins, PhD

    Sylva Collins, PhD

    • Director, Office of Biostatistics, OTS, CDER
    • FDA, United States

    Dr. Collins is the Director of the Office of Biostatistics, OTS/CDER/FDA. Prior to joining the FDA in August 2019, she has spent more than 30 years leading large global biometrics organizations and has contributed to dozens of successful regulatory submissions in multiple jurisdictions. She pioneered the large-scale deployment of electronic data capture at multiple companies including Bayer and Novartis. She implemented standardization of biometrics systems and processes for large pharma organizations to allow near simultaneous regulatory submissions globally. Sylva received her B.S. in Mathematics from the American University of Beirut, M.A. and Ph.D. in Statistics from Boston University, and M.S. in Computer Science from NYU.

  • Andrew  Potter, PhD

    Andrew Potter, PhD

    • Mathematical Statistician, OB, OTS, CDER
    • FDA, United States

    Dr. Andrew Potter is a mathematical statistician in the Division of Biometrics I in CDER supporting the review work in the Division of Psychiatry. His research interests include the use of digital health technologies in clinical trials and the analysis of high frequency outcome data and in involved in working groups at FDA on this topic. He received his PhD in Biostatistics from the University of Pittsburgh.

  • Jeremy A Rassen, DrSc, MS

    Jeremy A Rassen, DrSc, MS

    • President and Chief Science Officer
    • Aetion, United States

    Jeremy A. Rassen, ScD is a pharmacoepidemiologist with 25 years of academic and industry experience. He is co-founder, president, and chief science officer at Aetion, a health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies. Prior to founding Aetion, Dr. Rassen was Assistant Professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. He also worked in Silicon Valley in a variety of tech companies. Dr. Rassen received his bachelor’s degree in Computer Science from Harvard College and his master’s and doctorate degrees in Epidemiology from the Harvard T.H. Chan School of Public Health.

  • Sara L. Eggers, PhD

    Sara L. Eggers, PhD

    • Director, Decision Support and Analysis Team
    • FDA, United States

    Sara Eggers leads the Decision Support and Analysis Team withing FDA’s Center for Drug Evaluation and Research. This team contributes to the development and implementation of initiatives regarding human drug benefit-risk assessment, patient-focused drug development, risk evaluation and mitigation strategies, regulatory decision support, and other efforts. Before joining FDA in 2011, Sara conducted research and consulting in the area of decision science, stakeholder engagement, and risk communication. She has a Ph.D. in Engineering and Public Policy, with an emphasis on decision science, from Carnegie Mellon University

  • Miguel  Hernan, DrPH, MD

    Miguel Hernan, DrPH, MD

    • Professor
    • Department of Epidemiology, Harvard T.H. Chan School of Public Health, United States

    Miguel Hernán conducts research to learn what works to improve human health. Together with his collaborators, he designs analyses of healthcare databases, epidemiologic studies, and randomized trials. Miguel teaches causal inference methods at the Harvard T.H. Chan School of Public Health, where he is the Kolokotrones Professor of Biostatistics and Epidemiology. His edX course “Causal Diagrams” and his book “Causal Inference: What If”, with James Robins, are freely available online and widely used for the training of researchers. Miguel is an elected Fellow of the American Association for the Advancement of Science and of the American Statistical Association, Editor Emeritus of Epidemiology, and past Associate Editor of Biometrics and JASA.

  • Paul Michael Imbriano, PhD, MSc

    Paul Michael Imbriano, PhD, MSc

    • Mathematical Statistician
    • FDA, United States

    Dr. Imbriano works as a statistical reviewer supporting the therapeutic areas of GI and liver at the FDA. He joined the FDA after graduating in 2018 from the University of Michigan with a PhD in Biostatistics. His research work at the University of Michigan focused on missing data in observational studies.

  • Matilde  Kam, PhD

    Matilde Kam, PhD

    • FDA/CDER/OTS/OB/AIS, United States

    Matilde Kam, PhD., serves as the Associate Director for Analytics and Informatics for the Office of Biostatistics (OB) CDER/FDA. As Associate Director, Matilde has strategic and oversight responsibility for matters pertaining to analytics and informatics including data standards, data integrity and quality, data science, scientific computing and statistical programming activities in OB. Prior to joining FDA, Matilde had significant experience in building and overseeing highly effective statistics and analytics groups in the pharmaceutical industry. She is a Fellow of the American Statistical Association and has served in various leadership roles for the ASA Biopharm Section. She received her PhD in Statistics from Penn State University.

  • Mark S. Levenson, PhD

    Mark S. Levenson, PhD

    • Director, Division of Biometrics VII, Office of Biostatistics, OT, CDER
    • FDA, United States

    Mark Levenson is the Director of the Division of Biometrics 7 in the Office of Biostatistics/Office of Translational Sciences/Center for Drug Evaluation and Research of FDA. At FDA, he has been the primary reviewer or secondary reviewer on many major pre-market and post-market drug safety problems. He has contributed to the methodology of the application of meta-analysis and propensity score analysis to the regulatory setting. He is active in CDER’s efforts in the Sentinel Initiative, reducing prescription opioid abuse, and real-world evidence.

  • John  Scott, PhD, MA

    John Scott, PhD, MA

    • Director, Division of Biostatistics, OBE, CBER
    • FDA, United States

    John Scott is Director of the Division of Biostatistics in the FDA's Center for Biologics Evaluation and Research, where he has also served as Deputy Director and as a statistical reviewer for blood products and for cellular, tissue and gene therapies. He has authored or co-authored numerous articles in areas including Bayesian and adaptive clinical trial design and analysis, drug and vaccine safety, data and text mining, and benefit-risk assessment. He holds a Ph.D. in Biostatistics from the University of Pittsburgh, an M.A. in Mathematics from Washington University in St. Louis, and a B.A. in Liberal Arts from Sarah Lawrence College, and is Editor of the journal, Pharmaceutical Statistics.

  • Aracelis  Torres, PhD

    Aracelis Torres, PhD

    • Director, Quantitative Sciences
    • Flatiron Health, United States

    Aracelis Torres is Director of Quantitative Sciences at Flatiron Health, where her work over the past four years has focused on translation of real-world oncology data to generate evidence. She is also an Adjunct Professor at Columbia University Graduate School of Arts and Sciences, where she teaches a course on large-scale data processing and analysis. She received a Ph.D. in Cancer Epidemiology from Johns Hopkins Bloomberg School of Public Health and a Master’s degree in Chronic Disease Epidemiology from Yale University’s School of Public Health. Her research has focused on disparities and study design considerations for observational data.

  • Hao  Zhu, PhD

    Hao Zhu, PhD

    • Deputy Division Director
    • FDA, United States

  • Anubha  Gupta, PhD

    Anubha Gupta, PhD

    • Pharmacometrician/Clinical Pharmacologist
    • GSK, United Kingdom

    Anubha Gupta is a Director of Clinical Pharmacology Modelling and Simulation at GSK and is based in United Kingdom. She has 12 years of industry experience in applying model-based approaches to inform drug development. She obtained a PhD degree in clinical pharmacokinetics and drug therapy from Uppsala University, Sweden. She has keen interest in applying quantitative pharmacological principles in decision making at various stages of drug development from early to late phase of clinical development and promoting collaborations across different quantitative divisions.

  • Roger J. Lewis, MD, PhD

    Roger J. Lewis, MD, PhD

    • Professor and Chair, Department of Emergency Medicine
    • Harbor-UCLA Medical Center, United States

    Dr. Lewis is Professor and Chair in the Department of Emergency Medicine at Harbor-UCLA Medical Center and the Senior Medical Scientist at Berry Consultants, with expertise in the design and oversight of adaptive clinical trials. He is a member of the National Academy of Medicine, the Board of Directors for the Society for Clinical Trials, and the Blood Products Advisory Committee of the FDA/CBER. He has served as a member of the Medicare Evidence Development & Coverage Advisory Committee for CMS and chaired numerous data and safety monitoring boards (DSMB) for both federally-funded and industry-sponsored clinical trials. He has authored or coauthored over 240 original research publications, reviews, editorials, and chapters.

  • Peter Grant Mesenbrink, PhD

    Peter Grant Mesenbrink, PhD

    • Executive Director of Biostatistics
    • Novartis Pharmaceuticals Corporation, United States

    Peter Mesenbrink, PhD is an Executive Director of Biostatistics at Novartis Pharmaceuticals Corporation in East Hanover, New Jersey. Peter received his BS in Mathematics from UVM in 1989 and a PhD in Statistics from NCSU in 1995. He joined Novartis in 1995 and is currently Therapeutic Area Head of Biostatistics for Transplantation and Hepatology. He is currently the chair of the NASH Estimands Working Group for the Liver Forum. Peter has research interests in statistical methodology for estimands/handling of missing data, design of master protocols, and meta-analysis methods. He is currently Editor of the ASA Biopharm Report and part of the Statistical Expert Group for the International COVID-19 Data Alliance.

  • Tyler  Reynolds

    Tyler Reynolds

    • Digital Health Consultant
    • PA Consulting, United States

    Tyler is a life sciences management consultant at PA Consulting with a focus on digital health. His expertise spans the areas of strategic thinking, operating model design, process improvement, financial analysis, and project management. He’s consulted to organizations of varying size and complexity, ranging from Fortune 15 companies to boutique biopharmaceutical labs. Most recently, Tyler led a non-profit initiative managing a team of 40 digital health professionals from 15 pharmaceutical companies towards a goal of further enabling and accelerating the global use of digital health technologies in clinical research.

  • Telba  Irony, PhD

    Telba Irony, PhD

    • Deputy Director, Office of Biostatistics and Epidemiology, CBER
    • FDA, United States

    Telba is Deputy Director of the Office of Biostatistics and Epidemiology at CBER. She joined FDA to implement the use of Bayesian statistics for the regulation of medical devices and led the Decision Analysis initiative including Bayesian statistics, benefit-risk determinations, and science of patient input. Telba received the 2014 FDA Excellence in Analytical Science Award for spearheading innovative regulatory science studies culminating in the release of novel guidances, supporting policy decision making, and changing the submission review paradigm. She has a PhD from Berkeley, is a fellow of the American Statistical Association, and elected member of the International Statistical Institute.

  • Pandurang M Kulkarni, PhD

    Pandurang M Kulkarni, PhD

    • Chief Analytics Officer-R&D / Vice President-Biometrics
    • Eli Lilly and Company, United States

    Pandu Kulkarni obtained his PhD in Statistics at the LaTrobe University, Melbourne, Australia. He taught and did research in statistics at the University of South Alabama for 10 years and attained full professorship. He received grants from the Air Force for the development of techniques to evaluate and study the effects of environmental contaminants. He also received grants from NASA to study the effects of microgravity to see the effectiveness of exercise countermeasures in minimizing the effects of microgravity on astronauts. He joined Eli Lilly in 2000 and has held leadership positions within and outside of Statistics. He has published more than 50 articles in statistics and medical areas in peer reviewed journals.

  • Thomas A Louis, PhD

    Thomas A Louis, PhD

    • Professor of Biostatistics
    • John Hopkins Bloomberg SPH, United States

    FDA Expert Statistical Consultant. Applications include clinical trials, genomics, surveys, malaria prevention; environmental, health and public policy. Methods research emphases include Bayesian modeling, the analysis of observational studies, research synthesis and surveys. Honors and awards include President and also Honorary Life Member of the International Biometric Society; elected member of the International Statistical Institute; Fellow of the American Statistical Association, of the American Association for the Advancement of Science, of the Institute of Mathematical Statistics; an honorary degree from Hasselt University, Belgium.

  • Veronica  Miller, PhD

    Veronica Miller, PhD

    • Executive Director
    • Forum For Collaborative Research, United States

    Dr. Veronica Miller, ED of the Forum for Collaborative Research, and Professor at UCB SHP is a leading expert in regulatory science, engaging stakeholders from both sides of the Atlantic to advance the development of therapeutics and diagnostics for unmet medical need. The Forum collaborative model covers HIV, HCV, HBV, transplantation associated viral infections, NASH, PSC, and Rare Diseases. She teaches graduate courses in regulatory science and drug development. Previously, she directed the interdisciplinary HIV Research Group at the JW Goethe University in Frankfurt, Germany. Dr. Miller obtained a PhD in Immunology from the University of Manitoba, Canada. Dr. Miller has over 100 peer-reviewed publications.

  • Lothar  Tremmel, PhD

    Lothar Tremmel, PhD

    • VP, Quantitative Clinical Sciences and Reporting
    • CSL Behring, United States

    Dr. Tremmel worked in the pharmaceutical industry for over 25 years, where he built and led highly effective groups of statisticians, programmers, and data managers. He is currently the VP of Quantitative Clinical Sciences and Reporting at CSL Behring. Recent appointments include Statistical Head for Astra Zeneca’s Diabetes Portfolio, and VP of Statistics and Programing at Incyte. Dr. Tremmel provided technical leadership for >10 successful new drug applications and label extensions in the areas of CNS/Pain, Oncology, digestive / metabolic disease, and orphan diseases. Dr. Tremmel holds a Ph.D. from the university of Giessen, Germany, and he an active contributor to the DIA Safety Statistics Working group.

  • Frank  Bretz, PhD

    Frank Bretz, PhD

    • Distinguished Quantitative Research Scientist
    • Novartis Pharma AG, Switzerland

    Frank Bretz is a Distinguished Quantitative Research Scientist at Novartis. He has supported the methodological development in various areas of drug development, including dose finding, estimands, multiple testing, and adaptive designs. He was a member of the ICH E9(R1) Expert Working Group on 'Estimands and sensitivity analysis in clinical trials' and currently serves on the ICH E20 Expert Working Group on 'Adaptive clinical trials'.

  • Michael  Crutchlow, DrMed, MD

    Michael Crutchlow, DrMed, MD

    • Distinguished Scientist, Clinical Research
    • Merck & Co, Inc, United States

    Mike Crutchlow is an endocrinologist who has been in clinical research at Merck & Co. for the past 13 years. For the past 5 years, he has been in the late-stage clinical research group where he has served as the clinical and overall development team leader for multiple product development teams, including current oversight of a NASH development program.

  • Lisa  Lupinacci, PhD, MS

    Lisa Lupinacci, PhD, MS

    • Vice President, Late Development Statistics
    • Merck and Co., Inc., United States

    Lisa Lupinacci holds M.S. and Ph.D. degrees in Statistics from Virginia Tech. She is currently the Vice President of Late Development Statistics at Merck. In this capacity, she has oversight for study design and statistical analysis support for the Phase 2-5 clinical programs spanning all 9 therapeutic areas at Merck. In addition to her 19 years as a statistician, Lisa spent 4 years as a drug development team leader for several large infectious disease programs, an opportunity which gave her a much broader knowledge of drug development and much deeper insights into leadership.

  • Yong  Ma, PhD

    Yong Ma, PhD

    • Lead Mathematical Statistician, OB, OTS, CDER
    • FDA, United States

    Dr. Yong Ma has been a mathematical statistician at CDER FDA since 2015. She obtained her doctorate degree in Biostatistics from the George Washington University. Before Joining the FDA, she worked as an assistant research professor at George Washington University and her work was mostly on diabetes prevention studies which lead to numerous publications. After joining the FDA, she has been focusing on methodology tailored for post-marketing safety study such as causal inference and meta-analysis. In addition to her regulatory review work, she is also actively engaged in contemporary methodology research such as machine learning and natural language processing.

  • Andrew  Thomson, PhD, MA, MS

    Andrew Thomson, PhD, MA, MS

    • Statistician, Methodology Taskforce
    • European Medicines Agency, Netherlands

    Andrew Thomson is a statistician in the Taskforce dedicated to Data, Analytics and Methodology at the European Medicines Agency. He provides methodological advice and guidance across all stages of development, and across all therapeutic areas. He also is the lead of the Statistics subgroup of ICH E11A on pediatric extrapolation. Before joining EMA, he headed the Epidemiology Unit in the Vigilance and Risk Management of Medicines Division of the MHRA, the UK regulator and was also previously a Statistical Assessor within the Licensing Division of the MHRA

  • Amy  Xia, PhD

    Amy Xia, PhD

    • Vice President, Biostatistics, Design & Innovation
    • Amgen Inc., United States

    Amy Xia is Vice President, Biostatistics, Design & Innovation at Amgen. Amy has worked on designing, implementing, and analyzing Phase I-IV clinical trials as well as observational studies over the past two decades. Currently, she heads up the Biostatistics and Design & Innovation organizations in the Center for Design and Analysis at Amgen, providing leadership and holistic vision for strategic drug development and driving innovative program/study designs across Amgen’s portfolios for evidence generation and decision-making. Amy received her PhD in Biostatistics from the University of Minnesota, and her medical degree from Peking University, China.

  • Greg  Ball, PhD

    Greg Ball, PhD

    • Senior Principal Biostatistician
    • Merck & Co., Inc., United States

    Current research on blinded safety monitoring procedures emerged from early work at academic medical centers (MD Anderson and the Methodist Hospital) and CROs (Westat and Quintiles), developed into my college dissertation and continues to be developed in collaboration with statistical and clinical scientists from several pharmaceutical companies (Astellas, AbbVie and Merck). Established, with Bill Wang, the ASA Biopharm Safety Monitoring working group and have been pioneering the joint DIA-ASA Interdisciplinary Safety Evaluation (DAISE) scientific working group, to advocate for aggregate safety assessments and cross-disciplinary scientific engagement.

Contact us

Registration Questions?

Send Email

Additional Information

Biostatistics Industry Resource Kit